Authors: Gonzalez-Lopez, Laura¹; Sanchez-Hernandez, Julia²; Aguilar-Chavez, Erika²; Cota-Sanchez, Adolfo³; Lopez-Olivo, Maria⁴; Villa-Manzano, Alberto²; Ortega-Flores, Ricardo⁵; Espinoza-Magaña, Genadia⁶; Rojo-Contreras, Wendoline⁷; Cardona-Muñoz, Ernesto⁸; Gamez-Nava, Jorge⁹

Source: Rheumatology International, Volume 28, Number 12, October 2008 , pp. 1223-1228(6)

Publisher: Springer

Abstract:

We evaluated the prevalence and characteristics associated with hyperhomocysteinemia in ankylosing spondylitis (AS). Ninety-seven patients with AS were compared with 97 controls. The assessment included clinical characteristics, disease activity (BASDAI), functioning (BASFI), history of drugs, and erythrocyte sedimentation rate (ESR). Total serum homocysteine (tHcy) was determined by fluorescence polarization immunoassay. A higher frequency of hyperhomocysteinemia (>15 μmol/L) was observed in AS (12 vs. 1%, P = 0.002). In the multivariate analysis the risk for hyperhomocysteinemia was increased in patients with higher score of HAQ-S (OR = 5.27, 95% CI: 1.29-21.44) and higher ESR (OR = 1.09, 95% CI: 1.02-1.18). No statistical associations was observed between hyperhomocysteinemia with other variables including methotrexate or sulfasalazine utilization. In conclusion, this study found a significant prevalence of hyperhomocysteinemia in Mexican patients with AS mainly associated to a worst functional impairment. Further follow-up studies are required to evaluate the risk of cardiovascular disease in these patients.

Keywords: Hyperhomocysteinemia; Prevalence; Ankylosing spondylitis; BASFI

Document Type: Research article

DOI: http://dx.doi.org/10.1007/s00296-008-0687-4

Affiliations: 1: Department of Internal Medicine-Rheumatology, Hospital General Regional 110, Instituto Mexicano del Seguro Social (IMSS) and Postgraduate Program of Public Health Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico 2: Department of Internal Medicine-Rheumatology, Hospital General Regional 110, Instituto Mexicano del Seguro Social (IMSS) and Postgraduate Program of Pharmacology, Centro Universitario De Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico 3: Department of Blood Chemistry, Central Laboratory, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Mexico 4: Anderson Hospital, Houston, TX, USA 5: Department of Blood Chemistry, Hospital General Regional 110, IMSS, Guadalajara, Mexico 6: Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico 7: Hospital General de Zona 6, Instituto Mexicano del Seguro Social (IMSS) and Postgraduate Program of Medical Sciences, Universidad de Colima, Colima, Mexico 8: Department of Internal Medicine-Cardiology, Hospital General Regional 45, IMSS, Guadalajara, Mexico 9: Section for Clinical Studies in Musculoskeletal and Autoimmune Diseases, Clinical Epidemiology Research Unit, Hospital de Especialidades, IMSS, Postgraduate Public Health Sciences Program and Postgraduate Program of Pharmacology, Universidad de Guadalajara, Guadalajara, Mexico, Email: lauragl@mail.udg.mx

Publication date: 2008-10-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Medicine ,  Public Health
• By this author: Gonzalez-Lopez, Laura ;  Sanchez-Hernandez, Julia ;  Aguilar-Chavez, Erika ;  Cota-Sanchez, Adolfo ;  Lopez-Olivo, Maria ;  Villa-Manzano, Alberto ;  Ortega-Flores, Ricardo ;  Espinoza-Magaña, Genadia ;  Rojo-Contreras, Wendoline ;  Cardona-Muñoz, Ernesto ;  Gamez-Nava, Jorge

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers